The CAROLINA trial
Presenters: Julio Rosenstock, MD; Mark Espeland, PhD; Steven E. Kahn, MB, ChB; Nikolaus Marx, MD, FESC, FAHA; Bernard Zinman, CM, MD; Darren K. McGuire, MD, MHSc; Matthew C. Riddle, MD.
Monday 10 June: 16:30–18:30
CAROLINA (CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes) directly compared the cardiovascular safety/efficacy of linagliptin and glimepiride over a median follow-up of more than 6 years.
Thus, the findings will not only refine knowledge of the cardiovascular safety/efficacy of the dipeptidyl peptidase (DPP)-4 inhibitor class, but also help to clear up controversy surrounding the longer-term cardiovascular safety of sulfonylureas.
The trial sponsor has press-released the top-line findings, revealing that linagliptin was noninferior to glimepiride. The full results will be presented at ADA.
- Expert view | The CAROLINA trial: Make or break for sulfonylureas?
- External link | Published design and baseline characteristics of CAROLINA
- Quick guide | Round-up of the DPP-4 inhibitor CV outcome trials